Stock listing

Frankfurt:42Z Revolution Medicines, Inc. Aktie

German listing (Frankfurt) of Revolution Medicines, Inc. · home listing NASDAQ:RVMD

Follow Revolution Medicines, Inc. into a list and get an email when it puts out news.

Share price · FWB:42Z

€169.30 EUR +6.35 (+3.9%)

Close on Oct 30, 2026

Day range
€167.00 – €169.30 EUROct 30, 2026
Market cap
€36.29B EURAt the close on Oct 30, 2026 · price × 214.3M shares outstanding
Revolution Medicines, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:RVMD · Home$188.17 USD-3.14 (-1.6%)1,289,153$190.71$192.98$187.12$191.31Close on Nov 2, 2026
Frankfurt:42Z€169.30 EUR+6.35 (+3.9%)—€167.00€169.30€167.00€162.95Close on Oct 30, 2026
Ticker
Frankfurt:42Z
Asset type
Stock
Exchange
Frankfurt
Currency
EUR

What changed lately

Calls

Upcoming

  • Revolution Medicines (NASDAQ:RVMD) Q3 2026 Earnings Call

    Wed, Nov 04, 2026 · 4:30 PM ET

    Register

Replays

  • Revolution Medicines (NASDAQ:RVMD) Q2 2026 Earnings Call

    Wed, Aug 05, 2026 · 4:30 PM ET

    Watch Transcript

  • Revolution Medicines (NASDAQ:RVMD) Q1 2026 Earnings Call

    Wed, May 06, 2026 · 4:30 PM ET

    Watch Transcript

  • Revolution Medicines (NASDAQ:RVMD) Q4 2025 Earnings Call

    Wed, Feb 25, 2026 · 4:30 PM ET

    Watch Transcript

Latest news

Medicilon Presents Revolution Medicines with the "Excellence in Client Partnership Award"

Oct 30, 2026

Revolution Medicines to Participate in November 2026 Investor Conferences

Oct 27, 2026

Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026

Oct 23, 2026

Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026

Oct 21, 2026

Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer

Oct 20, 2026

Revolution Medicines’ RASONQUE™ (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer

Oct 15, 2026

Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer

Oct 5, 2026

Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer

Sep 14, 2026

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

Sep 2, 2026

U.S. FDA Approves Revolution Medicines' RASONQUE (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

Aug 27, 2026

All Revolution Medicines, Inc. news

Decks

Revolution Medicines, Inc. on 6ix

News releases
47 in the last 12 months · 172 in all · newest Oct 30, 2026 · oldest 2020
Calls
21 calls with a replay · 21 with a transcript · latest Aug 5, 2026
Decks
16 decks · latest Aug 26, 2026

Where Revolution Medicines, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:RVMD · Home listingNASDAQUnited StatesUSD
gettex:42ZgettexGermanyEUR
LS Exchange:A2PYWGLS ExchangeGermanyEUR
Milan:1RVMDMilanItalyEUR
Tradegate:42ZTradegateGermanyEUR
BX Swiss:RVMDBX SwissSwitzerlandCHF
BOATS:RVMDBOATSUnited StatesUSD
Lang & Schwarz:A2PYWGLang & SchwarzGermanyEUR
BMV:RVMDBMVMexicoMXN
Dusseldorf:42ZDusseldorfGermanyEUR
Frankfurt:42Z · This pageFrankfurtGermanyEUR
Hamburg:42ZHamburgGermanyEUR
Munich:42ZMunichGermanyEUR
Stuttgart:42ZStuttgartGermanyEUR
BIVA:RVMDBIVAMexicoMXN
Hanover:42ZHanoverGermanyEUR
Xetra:42ZXetraGermanyEUR

Log in to ask 6ix AI your own questions about Revolution Medicines, Inc.